Peer-reviewed veterinary case report
FGF-23 blood levels linked to kidney disease stages in cats
By Lin, Jiabao et al.·Published in Journal of Veterinary Diagnostic Investigation·2021·College of Veterinary Medicine, China Agricultural University, Beijing, China, China·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Serum fibroblast growth factor 23 (FGF-23): associations with hyperphosphatemia and clinical staging of feline chronic kidney disease
- Species:
- cat
Plain-English summary
A study looked at how a protein called fibroblast growth factor 23 (FGF-23) relates to chronic kidney disease (CKD) in cats. Researchers found that FGF-23 levels were higher in cats with CKD compared to healthy cats, and these levels increased as the disease progressed. They also noted that higher phosphorus levels were seen in cats with more advanced stages of CKD. This suggests that measuring FGF-23 could help veterinarians monitor kidney disease in cats and possibly detect issues before phosphorus levels rise.
People also search for: cat kidney disease symptoms · FGF-23 in cats · chronic kidney disease treatment for cats · high phosphorus in cat blood
Abstract
Fibroblast growth factor 23 (FGF-23) is an independent monitor of the progression of chronic kidney disease (CKD) in human medicine, and FGF-23 may have value as a biomarker in feline CKD. We evaluated the relationship between serum FGF-23 and CKD stages, and the effect of age on FGF-23 in normal cats. We measured FGF-23 and intact parathyroid hormone (iPTH) concentrations by ELISA, with intra- and inter-assay CVs ≤ 15%. The percentage recovery of FGF-23 and iPTH remained stable for up to 7 d in samples stored at −20°C and −80°C. We measured FGF-23 in 304 cats, among which 196 were diagnosed with CKD. The 108 clinically healthy cats were divided into 5 subgroups based on growth stage (0–2 y, 3–6 y, 7–10 y, 11–14 y, ≥ 15 y). No statistical difference was found in FGF-23 among age groups ( p = 0.15) or by sex in healthy subjects. Using the International Renal Interest Society guideline, 34 cats were defined as CKD stage 1, 74 stage 2, 51 stage 3, and 37 stage 4. FGF-23 was higher in cats in all CKD stages than in controls. Higher serum phosphorus was observed in stage 3 ( p = 0.04) and 4 ( p < 0.01) compared to controls. iPTH increased as CKD progressed. Pearson analysis indicated a positive linear relationship between FGF-23 and iPTH (control: r = 0.70, p < 0.01; CKD: r = 0.46, p = 0.02). FGF-23 may be a useful biomarker of feline CKD and may precede hyperphosphatemia in advanced feline CKD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1177/1040638720985563